CytoDyn: Prelim Results from Breast Cancer Treated with Leronlimab

 CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today strong preliminary results from its Phase 1b/2 trials and compassionate use with a total of 30 metastatic triple-negative breast cancer (mTNBC) patients. Patients in Phase 1b/2 were treated with leronlimab in combination with carboplatin.

Key findings from the interim 12-month analysis include the following:

72% of patients had a decrease in CAMLs (cancer-associated macrophage-like cells) ~30 days after induction of leronlimabThe decrease in CAMLs was associated with: A ~300% increase in mean progression-free survival (mPFS)A significant ~450% increase in overall survival (OS) at 12 monthsHigh CCR5 in tumor tissue biopsies may help to stratify patients likely to progress on leronlimabDecreases in CAMLs and CTCs (circulating tumor cells) appear to be related to slower progression and lower mortalityCAMLs appear to identify populations that are responding to leronlimab

Daniel Adams, Director of Clinical Research & Development, Creatv MicroTech, Inc., stated, “While these are only interim results at the 12-month point, our ability to rapidly monitor and identify patients that appear to respond to leronlimab using a single tube of blood is quite an encouraging finding. The fact that greater than 70% of patients saw positive changes in circulating tumor cells after a single dose of leronlimab was made even more informative by their dramatic increases in both progression-free survival and overall survival. The fact that a large group of patients taking leronlimab had an mPFS of approximately 6 months is well beyond that experienced with current treatment options available to these women, who typically have mPFS of approximately 2 months. This result is even more amazing as these women did not even reach mOS in 12 months, considering the typical mOS in this population is only 6 to 7 months.”

https://www.bakersfield.com/ap/news/cytodyn-announces-preliminary-results-from-30-mtnbc-patients-treated-with-leronlimab-decreases/article_e3a7633b-3eae-5487-98e9-4223be3b4c62.html